Search Results - "Behnan, Tanya T."

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults by Amrein, Philip C., Attar, Eyal C., Fell, Geoffrey G, Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven, Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S., Fathi, Amir T.

Get full text

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults by Amrein, Philip C., Ballen, Karen K., Stevenson, Kristen E., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven L., Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Connolly, Christine, Graubert, Timothy A., Neuberg, Donna S., Fathi, Amir T.

“…Introduction: While progress has been made in the treatment of childhood leukemia, the outlook for patients >60 years of age with acute lymphoblastic leukemia…”
Get full text

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults by Amrein, Philip C., Attar, Eyal C., Fell, Geoffrey, Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven L., Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S., Fathi, Amir T.

“…Introduction: Outcomes for acute myeloid leukemia (AML) among older patients has remained largely unchanged for decades. Long-term survival for patients aged…”
Get full text

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults by Amrein, Philip C., Ballen, Karen K., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno, McAfee, Steven L, Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Connolly, Christine, Neuberg, Donna S, Fathi, Amir T.

“…Introduction: While progress has been made in the treatment of childhood leukemia, the outlook for patients >60 years of age with acute lymphoblastic leukemia…”
Get full text

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults by Amrein, Philip C., Attar, Eyal C., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno, McAfee, Steven, Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S, Fathi, Amir T.

“…Introduction: Treatment of acute myeloid leukemia (AML) has remained largely unchanged for several decades despite the emergence of new agents. Long-term…”
Get full text

Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia by Fathi, Amir T., Blonquist, Traci M., Emadi, Ashkan, Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno, McAfee, Steven L, Hasserjian, Robert P., Preffer, Frederic I., Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Fishman, Kaitlyn, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Lesho, Patricia, Duong, Vu H., Mann, Mason, Lescinskas, Christopher, Connolly, Christine, Neuberg, Donna S, Ballen, Karen K., Amrein, Philip C.

“…Background: Brentuximab vedotin (BV) is an antibody-drug conjugate (ADC) consisting of an antibody specific for human CD30, an anti-microtubule agent…”
Get full text

Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia by Brunner, Andrew M., Blonquist, Traci M., DeAngelo, Daniel J., McMasters, Malgorzata, Winer, Eric S., Hobbs, Gabriela S., Amrein, Philip C., Hock, Hanno, Steensma, David P., Garcia, Jacqueline S., Luskin, Marlise R., Stone, Richard M., Ballen, Karen K., Rosenblatt, Jacalyn, Avigan, David E., McAfee, Steven L, Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Fishman, Kaitlyn, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Nelson, Nicole, Logan, Emma, Lombardi Story, Jennifer, Connolly, Christine, Neuberg, Donna S, Chen, Yi-Bin, Graubert, Timothy A., Fathi, Amir T.

“…▪ Background: Aurora kinases play essential roles in regulating cell division, and increased expression has been noted in myelodysplastic syndromes (MDS) and…”
Get full text